Phase III Comparison of Consolidation with IFN-A vs No Consolidation Following Intensive Induction Chemotherapy with ProMACE-MOPP with or without Radiotherapy in Patients with Stage III/IV Low-Grade non-Hodgkin's Lymphoma

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIITreatmentClosed16 and overNCISWOG-8809


I.  Compare the disease-free survival of patients with Stage III or IV 
low-grade non-Hodgkin's lymphoma randomly assigned to consolidation with 
interferon alpha vs. no consolidation therapy following intensive induction 
chemotherapy with ProMACE-MOPP 
mustard/procarbazine/methotrexate plus leucovorin rescue) with or without 

II.  Determine the CR rate, duration of response, and survival of patients 
with low-grade non-Hodgkin's lymphoma treated with ProMACE-MOPP.

III.  Compare the toxicities of induction with ProMACE-MOPP (with or without 
radiotherapy) vs. induction followed by consolidation with interferon in this 
patient population.

Entry Criteria

Disease Characteristics:

Biopsy-proven low-grade non-Hodgkin's lymphoma:
  Diffuse, small, lymphocytic
  Follicular, predominantly small cleaved cell
  Follicular, mixed small cleaved and large cell

Measurable, clinical or pathologic Stage III/IV disease

  At a minimum, peripheral hemogram, liver function tests,
  chest x-ray, abdominal CT, and bone marrow biopsy required
  for staging

Chronic lymphocytic leukemia not eligible

No known CNS disease

Prior/Concurrent Therapy:

Biologic therapy:
  No prior biologic therapy

  No prior chemotherapy

Endocrine therapy:
  Prior corticosteroid treatment allowed

  No prior radiotherapy

  Not specified

Patient Characteristics:

  16 and over

Performance status:
  SWOG 0-2

  Not specified

  Not specified

  Creatinine no more than 1.7 mg/dl
  Creatinine clearance at least 60 ml/min

  Normal cardiac function, i.e.:
     No history of severe heart disease
     No cardiomyopathy
     No CHF
     LVEF at least 50% by MUGA scan (only required if cardiac
     history is questionable)

  No prior malignancy that might recur and affect survival
  No AIDS or HIV-associated complex

Blood/body fluid analyses to determine eligibility and
imaging studies and physical exams for tumor measurement
completed within 14 days prior to registration; screening
exams other than blood/body fluid analyses and imaging
studies of nonmeasurable disease or uninvolved organs
completed within 42 days prior to registration

Repeat bone marrow exam required within 42 days of
registration if marrow exam negative 6 months prior to entry;
if marrow exam positive within 6 months prior to entry and no
interim treatment given, repeat marrow exam not required

Expected Enrollment

About 400 patients will have to be entered on Induction therapy in order to 
have the 252 patients required for randomization.  Accrual is anticipated to 
be complete in about 4 years.


All patients receive Induction chemotherapy on Regimen A, and those in PR with 
negative bone marrow after chemotherapy receive further Induction therapy with 
involved field irradiation on Regimen B; patients with PR and positive bone 
marrow receive additional chemotherapy, after which, if the marrow is negative 
and they are still in PR, they enter Regimen B.  All patients who achieve CR 
after treatment on either Regimen A or A and B and those patients with PR 
after treatment on Regimen B are randomized on Arms I and II.


Regimen A:  8-Drug Combination Chemotherapy plus Leucovorin Rescue.  
ProMACE-MOPP:  Cyclophosphamide, CTX, NSC-26271; Doxorubicin, DOX, NSC-123127; 
Etoposide, VP-16, NSC-141540; Mechlorethamine, Nitrogen Mustard, NM, NSC-762; 
Vincristine, VCR, NSC-67574; Procarbazine, PCB, NSC-77213; Prednisone, PRED, 
NSC-10023; Methotrexate, MTX, NSC-740; plus Leucovorin calcium, CF, NSC-3590.

Regimen B:  Radiotherapy.  Involved field irradiation using megavoltage 
equipment with minimum energies of Co60 or 2 MV x-rays.


Arm I:  Biological Response Modifier Therapy.  Interferon alpha (Schering), 
IFN-A, NSC-377523.

Arm II:  No further treatment.

Published Results

Fisher RI, Dana BW, LeBlanc M, et al.: Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. J Clin Oncol 18 (10): 2010-6, 2000.[PUBMED Abstract]

Dana BW, Unger J, Fisher RI, et al.: A randomized study of alpha-interferon consolidation in patients with low-grade lymphoma who have responded to pro-mace-MOPP (DAY 1--8) (SWOG 8809). [Abstract] Proceedings of the American Society of Clinical Oncology 17: A-10, 1998.

Related Publications

Hsi ED, Rimsza L, Goldman BH, et al.: MUM1 expression in follicular lymphoma is a poor prognostic marker in patients treated with immunochemotherapy (SWOG 9800/9911) but not chemotherapy alone (SWOG 8809): a Southwest Oncology Group correlative science study. [Abstract] Blood 112 (11): A-376, 2008.

Fisher RI, LeBlanc M, Press OW, et al.: New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23 (33): 8447-52, 2005.[PUBMED Abstract]

Trial Contact Information

Trial Lead Organizations

Southwest Oncology Group

Bruce Dana, MD, Protocol chair
Ph: 503-239-7767

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.